BioPharma Resources

Drug Trial Radar · NCT04808505

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to < 18 Years

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jul 18, 2023

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.

Conditions

  • Glycogen Storage Disease Type II Infantile Onset

Interventions

  • Cipaglucosidase alfaBiological

    Sterile lyophilized powder intravenous (IV) infusion

  • MiglustatDrug

    65 mg oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with infusion-associated reactions (IARs)Time frame: 104 weeks

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Florida Clinical Research Center

    Gainesville, Florida · Recruiting

  • The Emory Clinic

    Atlanta, Georgia · Recruiting

  • Duke University Early Phase Research Unit

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • UPMC Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • University of Utah, Clinical and Translational Sciences Institute

    Salt Lake City, Utah · Recruiting

  • Universitätsklinikum Gießen und Marburg GmbH, Zentrum fur Kinderheilkunde und Jugendmedizin Abteilung fur Kinderneurologic, Sozialpadiatric und Epileptologie

    Giessen, Germany · Recruiting

  • Universitätsklinikum Heidelberg - Pädiatrisches Klinisch-Pharmakologisches Studienzentrum (paedKliPS)

    Heidelberg, Germany · Recruiting

  • SphinCS GmbH

    Höchheim, Germany · Recruiting

  • Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin Albert-Schweitzer-Campus 1

    Münster, Germany · Recruiting

  • AOU Federico II

    Naples, Italy · Recruiting

  • Erasmus MC, Sophia Kinderziekenhuis

    Rotterdam, Netherlands · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Withdrawn

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.